Clinical Trial News and Research

RSS

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Biomet, a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, has enrolled the first subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI).

5 Jun 2010

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).

4 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

As part of a national clinical trial, UT Southwestern Medical Center researchers found little difference in effectiveness between two popular treatments for one of the most common ailments among American women: stress urinary incontinence.

4 Jun 2010

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

A team of investigators at Rational Therapeutics, Inc. and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

4 Jun 2010

Merck launches Oncology Collaborative Trials Network

Today, Merck announced the launch of the Merck Oncology Collaborative Trials Network, a pioneering clinical trial network focusing on the development of Merck drug and vaccine candidates being investigated for the treatment and prevention of cancer. The global network comprises leading cancer research centers who will partner with Merck to speed the development of innovative treatments for a range of cancers.

4 Jun 2010

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

Chemotherapy-induced amenorrhea in premenopausal women being treated for early stage breast cancer was associated with significantly improved patient survival, according to a study published this week in the New England Journal of Medicine by the National Surgical Adjuvant Breast and Bowel Project (NSABP) in collaboration with leading US cancer centers and cooperative cancer research groups.

4 Jun 2010

New therapy mounts double-barreled attack on leukemia, report UF researchers

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

4 Jun 2010

American Cancer Society and NPCRC award $1.8M for palliative care research

The American Cancer Society and the National Palliative Care Research Center (NPCRC) are awarding $1.8 million in research grants to researchers at 12 institutions for studies aimed at reducing suffering for seriously ill patients and their family caregivers. The studies will be conducted over the next two years. Since 2007, a collaborative effort by the organizations has awarded 51 grants totaling almost $7 million.

4 Jun 2010

YM BioSciences raises $3.2M through non-brokered private placement of common shares

YM BioSciences Inc., announced today that it has raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 common shares to be issued at US$1.27. The sale price is at no discount to the closing price of the shares on the NYSE Amex on June 1, 2010.

4 Jun 2010

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

Tioga Pharmaceuticals, Inc. announced today that the company has dosed its first subject in a Phase 3 clinical trial to evaluate asimadoline for the treatment of patients with diarrhea-predominant irritable bowel syndrome (DIBS). The trial, referred to as ASMP3001, is the first of two Phase 3 trials being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for U.S. registration. This first trial will be conducted at 120 sites in the U.S.

4 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

3 Jun 2010

Combined alcohol dependency treatments reduce social costs of health care: Study

Combining medications and behavioral interventions for treating alcohol-dependent patients reduces social costs of health care, arrests and motor vehicle accidents, according to a new study by researchers at RTI International, University of Wisconsin-Milwaukee, University of North Carolina at Chapel Hill, University of Pennsylvania and Yale University.

3 Jun 2010

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis.

3 Jun 2010

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

3 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company's highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of gastric cancer.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

BD Diagnostics, a segment of BD, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX™ GBS Assay for Group B Streptococcus on the BD MAX System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads for maximum lab efficiency and flexibility.

From BD (Becton, Dickinson and Company) 3 Jun 2010

Clinical Trial News and Research

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Merck launches Oncology Collaborative Trials Network

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

New therapy mounts double-barreled attack on leukemia, report UF researchers

American Cancer Society and NPCRC award $1.8M for palliative care research

YM BioSciences raises $3.2M through non-brokered private placement of common shares

Tioga commences dosing in Phase 3 trial of asimadoline for diarrhea-predominant irritable bowel syndrome

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Combined alcohol dependency treatments reduce social costs of health care: Study

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News